NCT03856372 is a NA clinical trial of Hypofractionated in Breast Cancer, sponsored by Fudan University.

Who is sponsoring NCT03856372?

NCT03856372 is sponsored by Fudan University.

What drugs are being tested in NCT03856372?

Interventions in NCT03856372: Hypofractionated, Conventional.

What condition does NCT03856372 study?

NCT03856372 studies Breast Cancer.

Is NCT03856372 still recruiting?

NCT03856372 is currently recruiting now. Last updated 27 February 2019.

Last reviewed 2019-02-27 · How we verify

NCT03856372

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hypofractionated Vs Conventional Fractionated Postmastectomy Radiotherapy for High Risk Breast Cancer

Recruiting now NA Last updated 27 February 2019

What this trial tests

NA trial testing Hypofractionated in Breast Cancer in 1,494 participants. Currently enrolling.

Timeline

1 September 2018

Primary endpoint
30 September 2023

30 October 2028

Quick facts

Lead sponsor	Fudan University
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	1,494
Start date	1 September 2018
Primary completion	30 September 2023
Estimated completion	30 October 2028
Sites	3 locations across China

Drugs / interventions tested

Hypofractionated
Conventional

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

Fudan University

Who can join

Adults 18 to 75, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study was designed to investigate whether hypofractionated adjuvant radiotherapy is noninferior to conventionally fractionated adjuvant radiotherapy in terms of efficacy and toxicities for high risk breast cancer patients treated with mastectomy

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Hypofractionated versus conventional intensity-modulated radiation irradiation (HARVEST-adjuvant): study protocol for a randomised non-inferior multicentre phase III trial.
Xie J, Xu F, Zhao Y, Cai G, et al · · 2022 · cited 9× · PMID 36581983 · DOI 10.1136/bmjopen-2022-062034
Post-mastectomy hypofractionated versus conventionally fractionated radiation therapy for patients receiving immediate breast reconstruction: Subgroup analysis of a phase III randomized trial.
Zhang X, Wang X, Chu Y, Zhang L, et al · · 2025 · cited 1× · PMID 39529653 · DOI 10.1016/j.ctro.2024.100882

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Fudan University trials

Trials by the same sponsor.

NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · not yet recruiting
NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre · Phase 2 · not yet recruiting
NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting
NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03856372 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fudan University
Last refreshed: 27 February 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03856372.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing